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Abstract 
 
Atrial fibrillation (AF) substantially increases the risk of stroke and other thromboembolic events. 
Hence, the vast majority of AF patients require appropriate antithrombotic prophylaxis. Oral 
anticoagulation (OAC) with either dose-adjusted vitamin K antagonist (VKA, e.g. warfarin) or non-
VKA oral anticoagulants (NOACs, e.g. dabigatran, apixaban, rivaroxaban) can be used for this 
purpose unless contraindicated. Therefore, stroke and bleeding risk assessment is an obligatory 
part of AF management and risk has to be weighed individually. Antiplatelet drugs (e.g. aspirin and 
clopidogrel) are inferior to OACs, both alone and in combination, with comparable risk of bleeding 
events.   Exclusion of the left atrial appendage as major source of embolism in AF is an alternative 
option for stroke prevention in the few high risk patients with contraindications for 
anticoagulation. 
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Key points 
 
 Prophylaxis of stroke and other thromboembolic events is central to the management of 
patients with AF. 
 All patients with AF but those with low stroke risk (non-valvular AF and CHA2DS2-VASc 
score = 0 in males, or 1 in females) require treatment with OACs unless they are contraindicated. 
 In patients CHA2DS2-VASc score = 1 apart from those getting the score of 1 by virtue of 
female gender OAC should be considered according to European guidelines however American 
guidelines support either OAC or aspirin or no antithrombotic therapy in this risk stratum. 
 Vitamin K antagonists and non-VKA OACs (NOACs, e.g. dabigatran, rivaroxaban, apixaban) 
can be administered depending on the clinical situation. 
 VKAs can be used in patients with either valvular or non-valvular AF, NOACs are approved 
for patients with non-valvular AF only. 
 No universal definition of non-valvular AF is available so far. Currently it states for AF in the 
absence of haemodynamically significant rheumatic valvular disease (first of all, mitral stenosis) or 
prosthetic mechanical heart valves. 
 Antiplatelet drugs either alone or in combination are inferior to OAC for antithrombotic 
prophylaxis but they have to be used in combination with OAC in AF patients undergoing 
percutaneous intervention with stent implantation.  
 In high risk patients with contraindications for anticoagulation left atrial appendage 
exclusion is an alternative option. 
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Introduction 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia which is associated with 
high morbidity and mortality.   The upward trend for AF prevalence translates into approximately 
3% of adults being affected with the arrhythmia in the more recent report.1,2 
AF confers a 5-fold elevated risk of stroke, which is characterized with prolonged hospitalizations, 
greater disability and higher mortality when associated with the arrhythmia in comparison with 
patients without AF.3 In the real life, involvement of AF in stroke development seems to be even 
more profound as in substantial proportion of so-called cryptogenic strokes AF has been detected 
via prolonged ECG monitoring as AF per se is often asymptomatic.4 
Oral anticoagulation (OAC) is the recommended effective option for the prevention of stroke and 
other thromboembolic events in AF, with either dose-adjusted vitamin K antagonists (VKA, e.g. 
warfarin) or non-VKA anticoagulants (e.g., dabigatran, apixaban, rivaroxaban, or edoxaban).5,6 
Antithrombotic prophylaxis with the adherence to guidelines improved significantly during the last 
decade but the rate of antiplatelet drugs administration instead of OAC remains significant, 
especially amongst the elderly and those at high bleeding risk. In the EURObservational Research 
Programme Atrial Fibrillation General Pilot Survey (EORP-AF), for example, 95.6% of patients 
amongst those with the CHA2DS2-VASc score ≥1, ie. with indications for OAC, received 
antithrombotic prophylaxis, with 80.5% amongst them were taking OAC.7 Another unfavorable 
trend found in the EORP-AF study was a common administration of combination of OAC with 
antiplatelet drugs in stable coronary artery disease (CAD).7 
The present article aims to provide an overview of current evidence for antithrombotic therapy in 
patients with AF. 
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Stroke and bleeding risk assessment 
Stroke risk is not homogeneous in AF patients. Thus, decision for initiation of OAC therapy has to 
be justified by patient’s individual risk assessment, and the net clinical benefit balancing stroke 
reduction against serious bleeding. A variety of risk factors for stroke development has been 
established, which subsequently gave the basis for the derivation of various stroke risk 
stratification schemes. 8,9 
The CHA2DS2-VASc score
10 (see the table 1 for acronym), is recommended by the 2012 ESC and 
2014 AHA/ACC/HRS guidelines for the management of AF as the only stroke risk assessment tool 
in patients with non-valvular AF.5,6 
The annual rate of thromboembolic events (including ischaemic stroke, pulmonary embolism and 
peripheral artery embolism) increased gradually with increasing CHA2DS2-VASc score, ranging from 
0.78 (95% confidence interval [CI] 0.58-1.04) per 100 person years with CHA2DS2-VASc = 0, rising to 
23.64 (95% CI 10.62-52.61) with CHA2DS2-VASc = 9.
11 
The major advantage of the CHA2DS2-VASc score in comparison to other stroke risk stratification 
schemes, including the older CHADS2 score (heart failure, hypertension, age ≥75 years, diabetes 
and stroke/transient ischaemic attack)12 is its ability to reliably distinguish the group of patients 
with a low risk of stroke, i.e. CHA2DS2-VASc score 0 for males or 1 for females, that has been 
validated in several large real-world AF cohorts.13-15 For example, in a retrospective analysis 
performed in the Danish nationwide cohort study which involved 19444 patients with CHADS2 
score=0, annual stroke rates ranged from 0.84 (95% CI 0.65-1.08) % in CHA2DS2-VASc score 0 to 3.2 
(95% CI 1.60-6.40) % in CHA2DS2-VASc score 3.
13 
Following the identification of these ‘truly low risk’ patients who do not need any antithrombotic 
therapy, effective stroke prevention (i.e. OAC) can be offered to those with ≥1 stroke risk factors 
given the positive net clinical benefit for these patients.16-18,53 Noteworthy, current American 
guidelines allow choice between OAC, aspirin or no antithrombotic therapy in patients with a 
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CHA2DS2-VASc score = 1.
6 On the contrary, European guidelines offer for consideration OAC only.5 
For AF patients with ≥1 stroke risk factors, the net clinical benefit of OAC therapy is positive, 
meaning that stroke risk reduction outweighs potential increase risk of haemorrhage. Moreover, 
the net clinical benefit is greater in patients with the higher bleeding risk; thus, high bleeding risk 
has not to be considered as a reason avoid OAC.16-18 
The HAS-BLED score (see the table 1 for acronym) has to be used for evaluation of individuals’ risk 
of major bleeding.19 This score performs well in comparison to other bleeding risk stratification 
schemes in different clinical settings: both AF and non-AF patients, warfarin or other 
anticoagulants, in case of bridging therapy.20-23 Also, it is able to predict ICH independently of 
other bleeding events.21,22 
Of note, risk stratification is a dynamic process and both stroke and bleeding risk should be 
assessed each time during patient’s follow-up. Also, the HAS-BLED score includes risk factors 
which can be modified and thus, reducing individual’s bleeding risk and potentially making OAC 
therapy safer.5,6 
 
Anticoagulation therapy 
Vitamin K Antagonists (e.g. warfarin) 
Until recently, the VKA class (eg. warfarin) were the only available OACs for stroke and 
thromboembolism prevention in AF patients. VKAs reduce stroke by 64 (95% CI 49-74) %, both in 
primary (2.7% annual absolute risk reduction) and secondary (8.4% annual absolute risk reduction) 
prevention, as well as all-cause mortality, by 26% (95% CI 3–43).24 
Warfarin inhibits the synthesis of the vitamin K-dependent coagulation factors (II, VII, IX, X) by 
interfering vitamin K reduction in the liver from vitamin K epoxide (inactive form that appears 
during oxidation of hydroquinone form) back to active one with the enzyme, called vitamin K 
epoxide reductase complex subunit 1 (VKORC1). Oxidation of hydroquinone form is coupled with 
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the posttranslational modification of vitamin K-dependent proteins which includes carboxylation 
of glutamic acid residues and formation of the γ-carboxyl glutamic acid domains. These domains 
are capable of binding calcium ions (with positive charge), thereby making proteins attractable to 
injured cells surface, which carries negative charge. Proteins lacking sufficient amount of calcium-
binding domains (partially carboxylated and decarboxylated) have significantly reduced coagulant 
activity.25 Pharmacological characteristics of warfarin are summarised in the table 2. 
Despite high antithrombotic efficacy, warfarin has a range of disadvantages, which make it 
inconvenient for use both from patients’ and clinicians’ point of view, specifically because of high 
intra- and inter-individual variability of anticoagulant effect (patient can develop bleeding 
complications with the minimal dose or may have warfarin resistance), food and drug interaction, 
slow onset of action, long half-life, etc.25 This results into significant underuse of warfarin in 
patients with AF in the real world, particularly if estimated bleeding risk is high, in association with 
CAD and in the elderly.7,26-28 
Genetic polymorphism of enzymes involved in the warfarin metabolism (cytochromes CYP2C9, 
CYP3A4, CYP2C19, CYP1A2) and target enzyme for warfarin (VKORC1) are of particular importance 
in its pharmacology, and several attempts have been made to develop algorithm for warfarin 
dosing based on pharmacogenetic approach, however, genetic testing cannot be applied routinely 
given the growing population with AF who requires OAC.29-31 
To reach optimal anticoagulation effect slow titration in the beginning of therapy and regular 
monitoring of international normalized ratio (INR) is required because of narrow therapeutic 
window for warfarin (INR 2.0-3.0). Time in therapeutic range (TTR) is used to evaluate quality of 
anticoagulation with warfarin and the average individual TTR has to be as high as >70% to expect 
efficacious stroke risk reduction with a low bleeding risk.32 For example, in 27458 patients taking 
warfarin from the UK General Practice Database, who spent at least 70% of time within 
therapeutic range, significantly lower stroke and mortality rate was achieved in comparison to 
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patients with <30% of time in range.33 Also, whilst translating data on warfarin effectiveness from 
clinical trials, it is important to keep in mind that TTR in real life population from every day 
practice is usually lower. In their systematic review Walraven et al found significantly more poor 
control in the community practices than either in anticoagulation clinics or clinical trials (-12.2%; 
95% CI -19.5 to -4.8).34 
 
Non-VKA oral anticoagulants 
Given the limitations of the VKAs, new classes of OACs have been developed, which allow 
overcoming the challenges of warfarin therapy as they selectively inhibit key factors in the 
coagulation cascade. These non-VKA oral anticoagulants (NOACs, previously referred to as new or 
novel OACs) include direct thrombin (factor II) inhibitors (e.g. dabigatran) and factor Xa inhibitors 
(e.g. apixaban, rivaroxaban and – most recently - edoxaban).35-37 
Direct thrombin inhibitors bind to active catalytic site of thrombin, either free thrombin in plasma 
or clot (fibrin)-bound thrombin, thereby interfering with multiple effects realized with thrombin: 
fibrin production from fibrinogen and its stabilization; activation of coagulation factors V, VIII, XI 
and XIII; platelet activation, inhibition of fibrinolysis, proinflammatory changes.38,39  
Factor X represents place of intrinsic and extrinsic coagulation pathways convergence. One 
molecule of activated factor Xa as a result of cascade of enzymatic reactions eventually leads to 
conversion of up to 1000 molecules of prothrombin to thrombin. Direct factor Xa inhibitors not 
only block free factor Xa via binding to its active site, but also inactivate it within the 
prothrombinase complex bound to platelets.38,39 
The principal differences of the NOACs from VKAs are the fixed dose administration and no need 
for intensive INR control, as well as a more rapid onset and shorter offset of action, fewer drug 
and no food interactions and kidney elimination.35-37 Pharmacological characteristics of the NOACs 
are summarised in the table 2. 
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Four large phase III prospective randomized clinical trials on the safety and effectiveness of NOACS 
in comparison to warfarin have been completed (Table 3): RE-LY with dabigatran40, ROCKET AF 
with rivaroxaban41, ARISTOTLE with apixaban42, and ENGAGE AF – TIMI 48 with edoxaban43 (see 
the Table 3 for acronyms). Trials on the oral direct factor Xa inhibitors were double-blind, 
whereas trial on dabigatran was open label between dabigatran and warfarin arms, but double 
blind between 2 arms with different doses of dabigatran (150 mg versus 110 mg bid). 
Patients in the ROCKET AF trial cohort were at higher stroke risk (based on the CHADS2 score), 
with more patients with the history of stroke, TIA or systemic embolism, and a lower mean TTR 
(55%).44 
All-cause (ischaemic, haemorrhagic or indeterminate) stroke and/or systemic (non-central 
nervous system) thromboembolic event were analysed as primary efficacy endpoint. Major 
bleeding (broadly defined as decrease of haemoglobin by at least 2 g/dl, transfusion of at least 
two units of red blood cells (within 24 hours in the ARISTOTLE trial), bleeding at a critical site or 
resulting in death) were used as primary safety end-point (clinically relevant non-major 
bleedings were accounted as well in the ROCKET AF trial ).40-43 
In the effectiveness analyses, all NOACs appeared to be noninferior to warfarin in the risk 
reduction in the primary endpoint of stroke or systemic embolism. However, apixaban and 
dabigatran 150 mg were found to be superior to warfarin.40,42 All NOACs appeared to be effective 
for secondary prophylaxis of stroke and/or TIA.45-47 
In the safety analysis the rate of major bleeding was found to be at least similar between NOACs 
and warfarin, or even significantly less with dabigatran 110 mg bid, apixaban and edoxaban, of 
note a reduced risk of intracranial haemorrhage was apparent for all NOACs.40-43 
A favorable trend in mortality was seen for all three NOACs compared to warfarin, which reached 
statistical significance when apixaban or edoxaban 60mg was used.40-43 Interestingly, a numerical 
but non-significant trend towards higher rate of myocardial infarction was found for dabigatran, 
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which was nonsignificant with inclusion of previously unidentified events40,48) and low-dose 
edoxaban43. 
As regards to long-term follow-up, dabigatran was further evaluated in the RELY-ABLE study, 
which included 5851 dabigatran-treated patients from the RE-LY study, followed-up for an 
additional 2.3 years, as well as in ‘real-world’ Danish nationwide cohort study, which both showed 
consistent results with the original trial.49,50 
In the meta-analysis of phase II and phase III randomized trials comparing NOACs versus VKAs 
these agents were found to reduce total mortality (relative risk [RR] 0.89, 95% CI 0.83–0.96), 
cardiovascular mortality (RR 0.89, 95% CI 0.82– 0.98), and stroke/systemic embolism (RR 0.77, 
95% CI, 0.70–0.86), intracranial hemorrhage (RR 0.46, 95% CI 0.39–0.56).51 These results are 
consistent with another systematic review using data from three pivotal studies (RE-LY, ROCKET 
AF, and ARISTOTLE): 8 (3 to 11) fewer deaths per 1000 patients (RR 0.88, 95% CI 0.82 to 0.96), 4 (2-
5 fewer) fewer hemorrhagic strokes per 1000 patients (RR 0.48, 95% CI 0.36 to 0.62) with obvious 
trend towards reduced risk of ischaemic stroke (RR 0.89, 95 CI% 0.78 to 1.02).52 Administration of 
the NOACs appeared to be particularly advantageous in patients with high risk of stroke and/or 
bleeding.53 Considering the noninferiority of the NOACs for stroke/thromboembolism prevention 
and better safety profile, the NOACs are given a preference over VKAs in current guidelines (Figure 
1).5 
Since no head-to-head studies have been conducted, there is no direct evidence of important 
differences of the efficacy and safety between the NOACs. Several indirect comparisons between 
dabigatran, rivaroxaban and apixaban have been carried out with broadly similar results obtained. 
These indirect comparisons found apixaban to be less causative of bleeding when compared with 
the dabigatran 150 mg or rivaroxaban. Also, rivaroxaban seemed to be less effective than 
dabigatran 150 mg for stroke prevention. There were no compelling differences between the 
NOACs in reduction in ischemic strokes or mortality.54,55 
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In another comparison analysis performed separately for primary and secondary prevention of 
stroke no significant differences in safety and efficacy endpoints between dabigatran 150 mg, 
rivaroxaban, and apixaban were found for secondary prevention, apart from higher rate of 
myocardial infarction with dabigatran 150 mg. For the primary prevention of stroke, there were 
some differences between the agents, e.g. apixaban was associated with more strokes in 
comparison with dabigatran 150 mg, but less major bleeding in comparison with both dabigatran 
150 mg and rivaroxaban.56 
In a recent indirect comparison of high dose edoxaban with other NOACs there were no significant 
differences in the efficacy endpoints (apart from higher rate of stroke, stroke or systemic 
embolism, haemorrhagic stroke when compared with dabigatran 150 mg). Higher rate of major 
and clinically relevant nonmajor bleeding was observed when compared with apixaban, but lower 
one, when compared with rivaroxaban. There were higher bleeding rates with all NOACs in 
comparison to low-dose edoxaban whilst it was less effective for stroke/systemic embolism 
prevention.57 
Importantly, limitations of indirect comparisons (differences in study design, patient population, 
definitions of outcomes) have been acknowledged in all analyses. 
The advantages of the NOACs in particular clinical situations may become disadvantageous. No 
need for anticoagulation monitoring may result in decreased patients’ adherence to treatment, 
that given the short half-lives of the NOACs place them at higher risk of adverse events. Also, there 
are no routine anticoagulation tests to evaluate reliably effect of the NOACs, which is essential in 
acute settings (e.g., acute ischaemic or haemorrhagic stroke). Those available in everyday practice, 
and supply physicians only with tentative qualitative information.36,58 
Also, there are no specific antidotes for NOACs. Prothrombin complex concentrates (either 
activated or non-activated) appeared to be standard for bleeding management for the NOACs.36 
Other reversal agents (anti-dabigatran antibody fragments, recombinant factor VIIa, factor Xa 
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missing Gla (carboxyglutamic acid) residues in Gla domains, etc) are mostly investigational thus far 
although early results appear promising.59  
Finally, the NOACs are currently approved for non-valvular AF  and are contraindicated in patients 
with severe kidney dysfunction (i.e. creatinine clearance <30 ml/min).5,6 
Defining non-valvular AF in clinical practice is a subject for controversy as no universal definition of 
non-valvular AF is available so far. European guidelines refer non-valvular AF to AF in the absence 
of rheumatic valvular disease (predominantly mitral stenosis) or prosthetic heart valves.5 
American guidelines define non-valvular AF as AF in the absence of rheumatic mitral stenosis, a 
mechanical or bioprosthetic heart valve, or mitral valve repair.6 Patients populations in pivotal 
trials on NOACs can be taken into account as well. Patients with moderate or severe mitral 
stenosis or prosthetic mechanical heart valve were excluded in all trials.40-43 However, in the RE-LY 
trial patients with any hemodynamically relevant valve disease were excluded.40 Also, ROCKET AF 
cohort included patients with annuloplasty with or without prosthetic ring, commissurotomy 
and/or valvuloplasty41, and ENGAGE AF-TIMI 48 - those with bioprosthetic heart valves and/or 
valve repair43. 
Given no compelling evidence for superiority of the NOACs over well-controlled VKA (i.e. high 
TTRs, >70%) and limited data of NOACs performance in the real-world population, attempts have 
been made to identify reliably proportion of AF patients who will reach a high TTR on VKA. The 
SAMe-TT2R2 score (Table 4) is a decision tool which may help to discriminate patients with 
anticipated high TTR (i.e. suitable for warfarin therapy) against those with anticipated low TTR (i.e. 
suitable for NOACs). 60,61 
 
Antithrombotic therapy 
Aspirin (acetylsalicylic acid) has previously been considered as an alternative to OACs, particularly 
in patients with moderate risk of stroke development62, i.e. up to 60% of AF population as being 
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classified with the CHADS2 score (congestive heart failure, hypertension, age ≥75, diabetes 
mellitus, stroke/TIA).63 
Aspirin use was supported by the results of few old trials, which together showed a non-significant 
relative risk reduction of stroke by of 19% (95% CI -1 to 35) in aspirin versus placebo/control, with 
no effect on all-cause mortality.  
The non-significant 19% reduction was driven by the results of only one single positive trial for 
aspirin, the SPAF I trial (Stroke Prevention in Atrial Fibrillation), which used aspirin 325 mg od and 
found a 42% of stroke risk reduction, vs control but with marked internal heterogeneity for the 
aspirin effect in the OAC-eligible and OAC-ineligible arms of SPAF-I.24  In SPAF-I, aspirin did not 
have any benefit in those age>75 nor did it prevent severe strokes.  Also, no significant reduction 
in stroke (either all stroke, ischaemic, disabling or fatal) nor all-cause mortality was found in 
Cochrane review.64  
More contemporary trials do not support aspirin use. Aspirin was found to be non-effective for 
stroke prevention in low-risk patients with AF in the Japan Atrial Fibrillation Stroke Trial.65 
Importantly, aspirin did not benefit the elderly in BAFTA trial (the Birmingham Atrial Fibrillation 
Treatment of the Aged Study) where warfarin was superior to aspirin, and importantly warfarin 
and aspirin had similar risks of major bleeding and intracranial haemorrhage.27  
Aspirin was also clearly inferior to apixaban in the AVERROES trial (Apixaban VERsus acetylsalicylic 
acid to prevent stroke in atrial fibrillation patiEntS who have failed or are unsuitable for vitamin K 
antagonist treatment), in which apixaban therapy resulted in 55% relative risk reduction in the 
stroke rate (particularly ischemic and disabling strokes) with no difference between aspirin and 
apixaban for major bleeding or intracranial haemorrhage.66,67  
Dual antiplatelet therapy of aspirin and clopidogrel may be marginally better than aspirin 
monotherapy – 11% (95% CI 2-19) % risk reduction for major vascular events (stroke, systemic 
embolism, myocardial infarction, death from vascular causes), 28% (95% CI 17-38) risk reduction 
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of stroke development was seen in the ACTIVE (Atrial fibrillation Clopidogrel Trial with Irbesartan 
for prevention of Vascular Events) trial for aspirin-clopidogrel combination therapy but at cost of 
increased major bleeding.68 However, the combination of aspirin and clopidogrel still remained 
inferior to OAC.69   Considering aforementioned assertions antiplatelet therapy as a mean of 
stroke prophylaxis is only recommend for AF patients unsuitable or with contraindications for any 
form of OAC (Figure 1).5   
 
Antiplatelet agents in AF patients, undergoing PCI/stenting 
The lower ability of antiplatelet drugs to prevent stroke and systemic embolism can perhaps be 
explained from pathophysiological point of view. Thrombi in AF are fibrin-rich and activation of 
coagulation factors plays greater role in their development than platelet activation. In contrast, 
platelet activation and development of platelet-rich thrombi is the hallmark of thrombotic 
complications in CAD (acute coronary syndrome [ACS], stent thrombosis, etc.).70-72 
Given the high prevalence of AF associated with CAD73 and need to undergo percutaneous 
intervention, often with stent implantation, these patients require therefore combination of OAC 
and anti-platelet agents (triple therapy) to cover both pathways and reduce risk of 
complications.74  
Obviously, triple therapy is associated with a higher risk of bleeding complications, and its duration 
of use depends on several factors including initial bleeding risk, type of stent (bare metal or drug-
eluting stent and its generation), clinical setting (ACS or elective procedure) to balance risk of 
bleeding and thrombotic/thromboembolic complications (Table 5).74 
Considering increased risk of major bleeding in triple therapy75-77 and low adherence to it 
(specifically, underuse of OAC)78, several studies attempted to compare effectiveness and safety of 
different prophylactic regimens against triple therapy.  Ре
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Broadly similar effectiveness and safety for triple therapy, dual antiplatelet therapy or warfarin 
plus single antiplatelet agent was observed in the AFCAS registry (Atrial Fibrillation Undergoing 
Coronary Artery Stenting) and Danish nationwide registries.79,80 In the WOEST study (What is the 
Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary 
StenTing) there was significantly lower bleeding rate and mortality was found in the warfarin plus 
clopidogrel arm versus triple therapy (HR 0.36, 95% CI 0.26–0.50 and HR 0.39, 95% CI 0.16–0.93, 
respectively) with no significant differences in the rate of thrombotic events.81 
However, these studies cannot change current practice as the data are non-conclusive (small 
sample, heterogeneity in design, combinations and doses of antithrombotic agents, etc.). Larger, 
prospective, randomized trials are required to prove the efficacy and safety of the various 
combinations of oral anticoagulants (including NOACs) and antiplatelet drugs (including newer 
P2Y12-receptor inhibitors prasugrel and ticagrelor). 
Noteworthy, in patients with stable CHD and AF, treated chronically with OAC, antiplatelet 
medications bring no significant benefits with respect to reduction of stroke, acute coronary 
events or mortality, but they are associated with increased risk of serious bleeding (HR 1.5 [95% CI 
1.23-1.82] for aspirin or HR 1.84 [95% CI 1.11-3.06] for clopidogrel), particularly ICH.82 
 
Nonpharmacological stroke and thromboembolism prevention 
A range of comorbidities may make patients with AF ineligible for chronic OAC (e.g., hepatic 
and/or kidney dysfunction, mechanical valve prostheses, hereditary coagulation disorders).  
Because the left atrial appendage (LAA) is known to be the major source of the stroke-causing 
thrombi in AF because of loss of coordinated contraction, dilation and blood stasis, LAA exclusion 
offers an alternative to OAC option for stroke prevention in AF.  
This can be achieved via percutaneous access (with closure devices) or during open heart surgery 
for any other reason (by ligating, stapling, amputation).83 Overall, LAA devices were found to be 
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noninferior to warfarin, for example WATCHMAN device (Boston Scientific, Natick, MA, USA) in 
the PROTECT AF study (LAA System for Embolic Protection in Patients With Atrial Fibrillation).84  
However, LAA occlusion may not eliminate completely risk of stroke because of other than LAA 
sources of thrombi85, which taken together with risk of procedural complications and scarce data 
allow to apply this option only for high stroke risk patients who are unable to tolerate OAC (Figure 
1)5 Surgical excision of LAA may be considered in patients undergoing cardiac surgery.6 
 
Conclusion 
Optimal prevention of thromboembolic events in vast majority of AF requires oral anticoagulation. 
With the NOACs became available antithrombotic prophylaxis seemed to overcome range of 
inconveniences associated with the warfarin treatment. The role of antiplatelet agents for stroke 
prevention in AF has diminished significantly but may still be required for the prevention of 
thrombotic complications in coronary disease, which appear to be common in AF. An informed 
assessment of the risk of stroke (using CHA2DS2-VASc) and bleeding (using HAS-BLED) is of 
importance when balancing risks and considering the net clinical benefit of thromboprophylaxis. 
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Table 1. Stroke and bleeding risk stratification with the CHA2DS2-VASc
10  and HAS-BLED19  scores 
 
CHA2DS2-VASc Score HAS-BLED Score 
Congestive heart failure/LV 
dysfunction 
1 Hypertension (systolic blood 
pressure >160 mmHg) 
1 
Hypertension 1 Abnormal renal or liver 
function 
1 or 2 
Age ≥75 years 2 Stroke 1 
Diabetes mellitus 1 Bleeding tendency or 
predisposition 
1 
Stroke/TIA/TE 2 Labile INRs (if on warfarin) 1 
Vascular disease (prior MI, 
PAD, or aortic plaque) 
1 Age (e.g., >65, frail condition) 1 
Aged 65–74 years 1 Drugs (e.g., concomitant 
antiplatelet or NSAIDs) or 
alcohol excess/abuse 
1 or 2 
Sex category (i.e. female 
gender) 
1   
Maximum score 9  9 
 
CHA2DS2-VASc: heart failure [moderate-to-severe left ventricular systolic dysfunction refer to left 
ventricular ejection fraction ≤40% or recent decompensated heart failure requiring 
hospitalization], hypertension, age ≥75, diabetes, stroke/transient ischaemic attack [TIA], vascular 
disease [specifically, myocardial infarction, complex aortic plaque and peripheral artery disease], 
age 65–74 years, female sex. 
HAS-BLED: uncontrolled hypertension, abnormal renal/liver function, stroke, bleeding history or 
predisposition, labile international normalized ratio [INR], elderly [e.g. age >65, frail condition], 
drugs [e.g., antiplatelet, non-steroidal anti-inflammatory drugs]/excessive alcohol. 
INR, international normalized ratio; LV, left ventricular; MI, myocardial infarction; NSAIDs, non-
steroidal anti-inflammatory drugs; TIA/TE, transient ischemic attack/thromboembolism; PAD, 
peripheral artery disease. 
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Table 2. Pharmacological characteristics of warfarin and non-VKA oral anticoagulants36,86-87 
Parameter Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban 
Mechanism of 
action 
Inhibition of 
VKORC1 
Direct thrombin 
inhibitor (free 
or bound), 
reversible 
Factor Xa 
inhibitor (free 
or bound), 
reversible 
Factor Xa 
inhibitor (free 
or bound), 
reversible 
Factor Xa 
inhibitor (free 
or bound), 
reversible 
Onset of action Slow, indirect 
inhibition of 
clotting factor 
synthesis 
Fast Fast Fast Fast 
Offset of action Long Short Short Short Short 
Absorption Rapid Rapid, acid-
dependent 
Rapid Rapid Rapid 
Bioavailability, 
% 
>95 6.5 >80 >50 62 
Tmax, hour 2.0-4.0 1.0-3.0 2.5-4.0 1.0-3.0 1.0-2.0 
Vd, L 10 60-70 50-55 21 >300 
Protein binding, 
% 
99 35 95 87 40-59 
T1/2β, hour 40 12-17 9-13 8-15 9-11 
Renal clearance None 80 35 27 50 
Non-renal 
clearance 
None 20 65 73 50 
CL/F, L/hour 0.35 70-140 10 5 30.2-33.7 
Accumulation in 
plasma 
Dependent on 
CYP2C9 
metabolic 
efficiency 
None None 1.3-1.9 Negligible 
Food effect No effect on 
absorption; 
dietary vitamin 
K influence on 
pharmacodyna
mics 
Delayed 
absorption with 
food with no 
influence on 
bioavailability 
Delayed 
absorption with 
food with 
increased 
bioavailability 
None None 
Age Yes, lower CL/F 
as age increases 
Yes, lower CL/F 
as age increases 
None Yes, lower CL/F 
as age increases 
NR 
Body weight Yes, higher dose 
for increased 
weight 
None None Yes, higher 
exposure with 
low body 
weight (< 60 kg) 
NR 
Sex Yes, lower CL/F 
in women 
Yes, lower CL/F 
in women 
None Yes, higher 
exposure in 
women 
NR 
Ethnicity Lower dose in 
Asian patients; 
higher dose in 
African-
American 
None Lower dose in 
Japanese 
patients 
None None Ре
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AF, atrial fibrillation; aPTT, activated partial thromboplastin test; BCRP, breast cancer resistance 
protein; bid, twice daily; CL/F, apparent clearance; CrCl, creatinine clearance; CYP, cytochrom P450 
isozymes; dTT, diluted thrombin test; ECT, ecarin chromogenic assay; EMA, European Medicines 
Agency; F, factor; FFP, fresh frozen plasma; INR, international normalized ratio; NR, not reported; 
qd, once daily; PCC, prothrombin complex concentrate; P-gp, P-glycoprotein; PT, prothrombin 
time; Tmax, time to maximum plasma concentration; TT, thrombin time; T1/2β, terminal half-life, Vd, 
volume of distribution; VKORC1, vitamin K epoxide reductase enzyme subunit 1. 
 
patients 
Drug 
transporter 
None P-gp P-gp, BCRP P-gp, BCRP P-gp 
CYP-mediated 
metabolism 
CYP2C9, 
CYP3A4, 
CYP2C19, 
CYP1A2 
None CYP3A4/5, 
CYP2J2 (equal) 
CYP3A4/5, 
CYP2J2 (minor), 
CYP1A2 (minor) 
CYP3A4 (4%) 
Drug-drug 
interactions* 
Numerous Potent P-gp 
inhibitors 
(verapamil, 
reduce dose; 
dronedarone: 
avoid) and 
inducers (avoid) 
Potent CYP3A4 
and P-gp 
inhibitors 
(avoid) and 
inducers (use 
with caution) 
Potent CYP3A4 
and P-gp 
inhibitors 
(avoid) and 
inducers (use 
with caution) 
Potent P-gp 
inhibitors 
(reduce dose) 
and inducers 
(avoid) 
Coagulation 
measurement 
INR TT, dTT, aPTT, 
ECA 
PT, anti-FXa anti-FXa PT, aPTT, anti-
FXa 
Reversal agents Vitamin K (slow 
reversal, 
prolonged 
inhibition), FFP 
or PCCs (rapid 
reversal) 
 
Activated 
charcoal or 
haemodialysis 
(overdose); 
PCCs or 
recombinant 
FVII 
(uncontrolled 
bleeding) 
Activated 
charcoal, FFP, 
PCCs, activated 
FVII 
 
Activated 
charcoal, FFP, 
PCCs, activated 
FVII 
Activated 
charcoal, FFP, 
PCCs, activated 
FVII 
Dosing for AF Individualised 
for each patient 
according to 
INR response 
(0.5-16 mg qd) 
150 mg bid or 
110 mg bid in 
high bleeding 
risk 
Contraindicated 
if CrCl < 30 
mL/min 
20 mg qd if CrCl 
> 50 mL/min or 
15 mg qd if CrCl 
15-50 mL/min 
5 mg bid or 2.5 
mg bid if  
 CrCl 15-
29 mL/min or 
 any 2 of 
the following 
are present:  
o age ≥ 80 
years 
o body 
weight ≤ 60 kg 
o serum 
creatinine ≥ 133 
ϕmol/L 
Awaiting EMA 
approval 
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*Potent inhibitors of CYP3A4 include antifungals (e.g., ketoconazole, intraconazole, voriconazole, 
posaconazole), chloramphenicol, clarithromycin, and protease inhibitors (e.g., ritonavir, 
atanazavir). P-gp inhibitors include verapamil, amiodarone, quinidine, and clarithromycin. P-gp 
inducers include rifampicin, St. John’s wort (Hypericum perforatum), carbamazepine, and 
phenytoin. Potent CYP3A4 inducers include phenytoin, carbamazepine, phenobarbital, and St. 
John’s wort.  
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Table 3. Summary of pivotal clinical trials of non-VKA oral anticoagulants in patients with 
nonvalvular AF 
Clinical trial RE-LY40 ROCKET AF41 ARISTOTLE42 ENGAGE AF - TIMI 4843 
Non-VKA OAC 
examined  
Dabigatran Rivaroxaban Apixaban Edoxaban 
Patients  18113 14 264 18 201 21105 
Age, years  71 73 70 72 
Mean CHADS2 
score  
2.1 3.5 2.1 2.8 
Non-VKA OAC 
dosing arm  
110 mg bid 150 mg bid 20 (15*) mg 
qd 
5 (2.5**) mg 
bid 
60 mg qd 30 mg qd 
Prior vitamin K 
antagonist 
treatment, %  
50 62 57 58.8 59.2 
Prior stroke or 
transient ischemic 
attack, %  
20 (including systemic 
embolism) 
55 19 (including 
systemic 
embolism) 
28.1 28.5 
Mean TTR, warfarin 
arm; %  
64 55 62 68.4 
Relative risk (95% CI) for non-VKA OAC versus warfarin 
Stroke or systemic 
embolism 
0.90 (0.74-
1.10) 
0.65 (0.52-
0.81) 
0.88 (0.75-
1.03) 
0.79 (0.66-
0.96) 
0.87 (0.73-
1.04) 
1.13 (0.96-
1.34) 
Major bleeding  0.80(0.70-
0.93) 
0.93 (0.81-
1.07) 
1.04 (0.90-
1.20) 
0.69 (0.60-
0.80) 
0.80 (0.71-
0.91) 
0.47 (0.41-
0.55) 
Intracranial 
hemorrhage  
0.30 (0.19-
0.45) 
0.41 (0.28-
0.60) 
0.67 (0.47-
0.93) 
0.42 (0.30-
0.58) 
0.47 (0.34-
0.63) 
0.30 (0.21-
0.43) 
Gastrointestinal 
bleeding 
1.09 (0.85-
1.39) 
1.49 (1.19-
1.88) 
1.47 (1.20-
1.81) 
0.88 (0.67-
1.14) 
1.23 (1.02-
1.50) 
0.67 (0.53-
0.83) 
Myocardial 
infarction  
1.29 (0.96-
1.75) 
1.27 (0.94-
1.71) 
0.81 (0.63-
1.06) 
0.88 (0.66-
1.17) 
0.94 (0.74-
1.19) 
1.19 (0.95-
1.49) 
Death  0.91 (0.80-
1.03) 
0.88 (0.77-
1.00) 
0.85 (0.70-
1.02) 
0.89 (0.80-
0.99) 
0.92 (0.83-
1.01) 
0.87 (0.79-
0.96) 
ARISTOTLE, Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial 
fibrillation; bid, twice daily; CHADS2, congestive heart failure, hypertension, age >75 years, 
diabetes mellitus, stroke or transient ischemic attack (2 points); CI, confidence interval; ENGAGE 
AF – TIMI 48 Effective aNticoaGulation with factor Xa next GEneration in Atrial Fibrillation – 
Thrombolysis In Myocardial Infarction 48; OAC, oral anticoagulant; qd, once daily; RE-LY, 
Randomized Evaluation of Long-term anticoagulation therapy; ROCKET AF, Rivaroxaban Once daily 
oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and 
Embolism Trial in Atrial Fibrillation; TTR, time in therapeutic range. 
* in patients with creatinine clearance 30 to 49 mL/min. 
** in patients with 2 or more of the following criteria: age >80 years, body weight <60 kg, or serum 
creatinine >133 ϕmol/L. 
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Table 4. Quality of anticoagulation control assessment with the SAMe-TT2R2score
60 
Risk factors Score 
Sex category (i.e. female gender) 1 
Age <60 years 1 
Medical history (≥2 of the following: hypertension, DM, CAD/MI, PAD, 
CHF, previous stroke, pulmonary, hepatic or renal disease) 
1 
Treatment with interacting drugs(e.g., amiodarone) 1 
Tobacco use (within 2 years) 2 
Race (i.e. non-caucasian) 2 
Maximum score 8 
 
CAD, coronary artery disease; CHF, congestive heart failure; DM, diabetes mellitus; MI, myocardial 
infarction; PAD, peripheral artery disease 
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Table 5. Recommended antithrombotic strategies following coronary artery stenting in patients 
with atrial fibrillation at moderate-to-high thromboembolic risk  
(adapted from Lip et al. 74) 
Haemorrhagic 
risk 
Clinical 
setting 
Stent 
implanted 
Recommendations in timeline 
Triple therapy of 
warfarin (INR 
2.0–2.5) + aspirin 
≤ 100 mg/day + 
clopidogrel 75 
mg/day 
Dual therapy of 
warfarin (INR 
2.0–2.5) + 
clopidogrel 75 
mg/day (or 
aspirin 100 
mg/day) 
Monotherapy 
of warfarin 
(INR 2.0–3.0) 
Low or 
moderate 
Elective 
Bare metal 1 month - 
Lifelong 
Drug eluting 3-6 months 12 months 
ACS 
Bare metal / 
Drug eluting 
6 months 12 months 
High 
Elective 
Bare metal* 
2-4 weeks - 
Lifelong 
ACS 4 weeks 12 months 
 
* drug eluting stents should be avoided 
ACS, acute coronary syndrome; INR, international normalized ratio. 
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Figure 1. Recommendations for prevention of thromboembolism in non-valvular AF5 
 
* 2014 AHA/ACC/HRS guideline for the management of patients with AF allows either OAC or 
aspirin or no antithrombotic therapy in patients with a CHA2DS2-VASc score = 1
6 
† currently not in the guidelines 
Solid line, best option; dashed line, alternative option.  
 
CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, 
stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74 years, sex category 
Patient 
with AF 
Valvular 
AF 
Dose-adjusted 
VKA  
Nonvalvular 
AF 
CHA2DS2-VASc score 
(with consideration of HAS-BLED 
score and patients preferences 
0 for males, 1 for 
females (lone AF, 
age<65 years) 
No antithrombotic 
prophylaxis 
required 
≥1 for males, >1 for females*  
Dose-
adjusted 
VKA  
Patient accepts OAC, no 
contraindications 
NOAC 
Patient refuses 
OAC 
Contraindications for OAC 
1 for males, 
2 for females 
>1 for males, 
>2 for females 
Aspirin – clopidogrel combination 
or - less effectively – aspirin 
monotherapy 
Surgical LAA 
closure or 
excision 
SAMe-TT2R2 score† 
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(female); HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding 
history or predisposition, labile international normalized ratio, elderly (≥65 years old), 
drugs/alcohol concomitantly (1 point each); SAMe-TT2R2, female sex, age less than 60 years, 
medical history (2 of the following: hypertension, diabetes, coronary artery disease/myocardial 
infarction, peripheral artery disease, heart failure, previous stroke, pulmonary, hepatic or renal 
disease), treatment with interacting drugs (e.g. amiodarone), tobacco use (within 2 years, 
doubled), non-Caucasian race (doubled). 
 
LAA, left atrial appendage; NOAC, novel (non-VKA) oral anticoagulant; OAC, oral anticoagulation; 
VKA, vitamin K antagonist 
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